Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986158 + fedratinib
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986158 + fedratinib is an investigational **combination therapy** being studied for intermediate- or high-risk myelofibrosis. BMS-986158 is an orally bioavailable, potent, and selective small-molecule BET (bromodomain and extra-terminal domain) inhibitor that modulates gene expression via epigenetic mechanisms. Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor approved for myelofibrosis. The combination targets two distinct pathways—BET-regulated transcription and JAK-STAT signaling—to enhance disease modification. Trials show acceptable safety and preliminary efficacy in patients refractory, relapsed, or intolerant to prior ruxolitinib (another JAK inhibitor), with endpoints including spleen volume reduction and modulation of JAK2 variant allele frequency[1][3][5][7].
- Brand names
- Inrebic (fedratinib)
- Other names
- BMS-986158 + fedratinib
02
Targets
BRD (Bromodomain-containing protein family)JAK2 (Janus kinase 2)
Beyond the preview
Go deeper on BMS-986158 + fedratinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986158 + fedratinib.